Microbiosci is a leading company offering the best Mycobacterium gene expression service. Our talented scientists are professional and experienced in Mycobacterium research. They would research closely with you to assist with designing and optimizing your custom synthetic biology project.
Mycobacterium tuberculosis is the most important of the pathogen responsible for an overwhelming burden of disease. Identifying the various target genes involved in these processes is significant to understand the pathogenesis of tuberculosis. The better understanding of essential metabolic pathways from M. tuberculosis is helpful to the development of novel therapeutic and prophylactic strategies to combat TB.
Fig.1. Role of PtpA, PtpB, and SapM for the infection cycle of Mycobacterium marinum in Dictyostelium discoideum.
pMV261 and pMV361 vectors both have an E. coli origin of replication, a kanamycin (Km) resistance gene and the hsp60 promoter. The difference is that pMV261 is a replicative vector containing the pAL5000 origin of replication and pMV361 is an integrative vector containing an attachment site and the origin of replication genes from mycobacteriophage L5.
Fig.2. Extrachromosomal (pMV261) and integrative (pMV361) expression vectors
1. Amplify or synthesize target genes
2. Construction of expression vectors (pMV261 & pMV361)
What we could help
• Gene expression
• Fluorescent marker gene expression
• Construct complementation strains
• Genome editing
Microbiosci is the premier institution to provide professional and comprehensive Mycobacterium gene expression services. We have years of experience to meet your specific project needs in using the synthetic biology to add value to your research project. Microbiosci thrives on being able to offer an individual solution for you to help you every step in the workflow around your gene of interest. Consequently, At Microbiosci, simply let us know your specific project needs. We will propose the best strategy for you.
1. Movahedzadeh, F. , Frita, R. , & Gutka, H. J. . (2011). A two-step strategy for the complementation of m. tuberculosis mutants. Genetics and Molecular Biology, 34(2), 286-289.
2. Stover CK1, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP,Young JF, Lee MH, Hatfull GF, et al. New use of BCG for recombinant vaccines. Nature,1991, 351(6326):456-460.